Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.47 |
| ▸ | PNP | P00491 | 4/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28695644 | 0.85 | XDH (0.43) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL986800 | 0.84 | XDH (0.60) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL5607948 | 0.84 | XDH (0.31) | XDHALDH1A1 | |
| SCHEMBL3953063 | 0.84 | XDH (0.38) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL15005119 | 0.83 | XDH (0.59) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL4899457 | 0.81 | XDH (0.44) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL27594330 | 0.80 | HPRT1 (0.42) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL1831279 | 0.80 | XDH (0.50) | XDHPNPTK1BLMUSP2 | |
| SCHEMBL1426626 | 0.77 | FDPS (0.34) | PNPUSP2TSHRHBBMEN1 | |
| SCHEMBL8421362 | 0.77 | TK1 (0.31) | XDHTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023241051-A1 | FLUORESCENTLY LABELED COMPOSITE SGRNA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 图维生物医药科技(苏州)有限公司 | 2023-12-21 | — | — | WO | claimed |
| US-20240226275-A1 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNAimmune, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118302181-A | Multigang TP53 and PAN-RAS mRNA cancer vaccine | 达冕生物有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4388017-A1 | COMPOSITIONS AND METHODS FOR ANTI-VIRUS CHIMERIC ANTIGEN RECEPTOR | Rudd, Christopher E. (CA) | 2024-06-26 | — | — | EP | disclosed |
| EP-4384214-A2 | COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | Rnaimmune, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118119930-A | Compositions and methods for mRNA vaccines against novel coronavirus infection | 达冕生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240156947-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097259-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097894-A1 | COMPOSITIONS AND METHODS OF RIBONUCLEIC ACID VACCINES ENCODING NYE-SO-1 | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4351615-A2 | MULTIPLEXED TP53 AND PAN-RAS MRNA CANCER VACCINES | Rnaimmune, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-0472498-A1 | Monoclonal antibodies to leptosphaeria | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| EP-0465415-A2 | Monoclonal antibodies to mycosphaerella species | CIBA-GEIGY AG (CH) | 1992-01-08 | — | — | EP | disclosed |
| US-4879217-A | MONOCLONAL ANTIBODIES FOR IMMUNOASSAY | AGRI-DIAGNOSTICS ASSOCIATES (US) | 1989-11-07 | — | — | US | disclosed |
| US-4845197-A | IMMUNOLOGICAL DETECTION OF FUNGAL PLANT DISEASES | AGRI-DIAGNOSTICS ASSOCIATES (US) | 1989-07-04 | — | — | US | disclosed |
| US-4803155-A | DETECTION OF PATHOGENIC FUNGUS IN TURFGRASS, USING AN ANALYTICALLY DETECTABLE LABELLED ANTIBODY-ANTIGEN COMPLEX | AGRI-DIAGNOSTICS ASSOCIATES (US) | 1989-02-07 | — | — | US | disclosed |
| EP-0292719-A2 | A test for rhizoctonia brown and yellow patch | DNAP DIAGNOSTICS, INC. (a Delaware corporation) (US) | 1988-11-30 | — | — | EP | disclosed |
| EP-0234501-A2 | Monocional antibodies and methods for fungal pathogen detection | DNAP DIAGNOSTICS, INC. (a Delaware corporation) (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0222998-A2 | Monoclonal antibodies and methods for fungal pathogen detection | DNAP DIAGNOSTICS, INC. (a Delaware corporation) (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4564597-A | Anti-Sm hybridoma | RESEARCH CORPORATION (US) | 1986-01-14 | — | — | US | disclosed |
| US-4246408-A | Imidazo[1,2-a]-s-triazine | ICN PHARMACEUTICALS (US) | 1981-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156947-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RBM22, RNGTT, RBM25 | XDH 4723/4885PNP 200/4885TK1 4555/4885 |
| US-20240226275-A1 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNGTT, SARS1, ACE2 | XDH 4757/4885PNP 241/4885TK1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.